Filing Details
- Accession Number:
- 0001179110-10-009260
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-05-25 13:00:00
- Reporting Period:
- 2010-05-24
- Filing Date:
- 2010-05-25
- Accepted Time:
- 2010-05-25 16:47:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
815094 | Abiomed Inc | ABMD | Surgical & Medical Instruments & Apparatus (3841) | 042743260 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1286370 | R Michael Minogue | C/O Abiomed, Inc., 22 Cherry Hill Drive Danvers MA 01923 | President, Ceo, Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, $.01 Par Value | Disposition | 2010-05-24 | 4,491 | $9.10 | 203,600 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Reported Derivative Holdings
Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | $9.05 | 2005-04-05 | 2014-04-05 | 100,000 | 100,000 | Direct |
Common Stock | Stock Option (right to buy) | $9.05 | 2005-04-05 | 2014-04-05 | 192,200 | 186,383 | Direct |
Common Stock | Stock Option (right to buy) | $9.05 | 2005-04-05 | 2014-04-05 | 100,000 | 100,000 | Direct |
Common Stock | Stock Option (right to buy) | $9.36 | 2006-06-08 | 2015-06-08 | 100,000 | 100,000 | Direct |
Common Stock | Stock Option (right to buy) | $13.57 | 2007-06-01 | 2016-06-01 | 260,000 | 260,000 | Direct |
Common Stock | Stock Option (right to buy) | $11.27 | 2008-05-30 | 2017-05-30 | 85,000 | 85,000 | Direct |
Common Stock | Stock Option (right to buy) | $13.80 | 2009-05-23 | 2018-05-23 | 43,333 | 43,333 | Direct |
Common Stock | Stock Option (right to buy) | $18.63 | 2009-06-15 | 2018-08-13 | 93,750 | 93,750 | Direct |
Common Stock | Stock Option (right to buy) | $5.86 | 2010-05-28 | 2019-05-28 | 148,000 | 148,000 | Direct |
Common Stock | Stock Option (right to buy) | $5.86 | 2010-03-31 | 2019-05-28 | 130,500 | 130,500 | Direct |
Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
---|---|---|---|
2014-04-05 | 100,000 | 100,000 | Direct |
2014-04-05 | 192,200 | 186,383 | Direct |
2014-04-05 | 100,000 | 100,000 | Direct |
2015-06-08 | 100,000 | 100,000 | Direct |
2016-06-01 | 260,000 | 260,000 | Direct |
2017-05-30 | 85,000 | 85,000 | Direct |
2018-05-23 | 43,333 | 43,333 | Direct |
2018-08-13 | 93,750 | 93,750 | Direct |
2019-05-28 | 148,000 | 148,000 | Direct |
2019-05-28 | 130,500 | 130,500 | Direct |
Footnotes
- Grant to reporting person of option to buy shares of Common Stock under the ABIOMED, Inc. 1998 Equity Incentive Plan.
- Grant to reporting person of option to buy shares of Common Stock under the ABIOMED, Inc. 2000 Stock Incentive Plan.
- Grant to reporting person of inducement option to buy shares of Common Stock under NASDAQ Marketplace Rule 4350. These options were granted outside of the Company's established stock option plans.
- These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6.
- Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
- These options become exercisable based on the achievement of certain performance milestones.
- These options become exerciseable upon the achievement of a certain performance milestone, based on the results of Abiomed's fiscal year ended March 31, 2010.
- Sale of common stock pursuant to reporting owner's 10b5-1 plan to pay tax liability upon vesting.
- This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $9.10 and $9.12. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the issuer, or a security holder of the issuer.